In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sun Pharmaceutical Agrees To Settle Out Of Court with Novartis over Exelon (India)

This article was originally published in PharmAsia News

Executive Summary

Sun Pharmaceutical Industries agreed to an out-of-court settlement with Novartis over the Indian drug maker's efforts to market a generic of the Novartis drug Exelon (rivastigmine tartrate) for treating Alzheimer's disease. In doing so, Sun joins several other major Indian generics makers in agreeing to an out-of-court settlement with Novartis over Exelon. Sun won U.S. FDA fast-paced approval as the first generic to file, but it and Ranbaxy Laboratories and Dr. Reddy's, as well as U.S.-based Watson Pharmaceuticals, challenged the Novartis patent for Exelon and since reached settlements. Most of the settlements have allowed the generics to market their versions if the innovator gets a share. (Click here for more

You may also be interested in...



Moderna Marches First Coronavirus Vaccine To US Test

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.

SK Bio Begins New Coronavirus Vaccine Development Using Versatile Platform

Korean vaccine specialist SK Bioscience moves to develop versatile platform technology to deal with outbreaks of infectious diseases such as the new coronavirus, as the number of infections in the country surges.

QUOTED. 25 February 2020. David Maman.

Israel-based Binah.ai hopes to earn regulatory approval for a video-based monitoring app that can detect vital signs in minutes. See what Binah.ai's co-founder and CEO, David Maman, said about the technology here.   

UsernamePublicRestriction

Register

SC065876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel